Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 31, 2004 Charly Travers	Hidden Value With QLT The market might overlook the drug maker's promising programs. Over the next six months, biotech investors should keep an eye on this one.
The Motley Fool April 25, 2005 Charly Travers	Where Is QLT going? The drug maker's upcoming conference call needs to address the question. Shares are down 30% since the beginning of the year. Can QLT turn this around?
The Motley Fool October 26, 2006 Brian Lawler	QLT Quickly Losing Traction The biotech company gets hammered by a competitor's superior product. There was one bright spot in the quarter for QLT, though. Investors, take note.
The Motley Fool February 23, 2005 Charly Travers	QLT Is Still a Value The market's concerns mean this Canadian drug company is being offered up at a great price.
The Motley Fool July 5, 2006 Brian Lawler	Stay Away From QLT Competitive pressure on its top drug makes this company one investors should avoid.
The Motley Fool January 22, 2007 Brian Lawler	QLT's Sagging Sales The drug developer's macular degeneration treatment has seen declining sales. And as sales fall, so too does the percent of profits that QLT keeps. Investors, take note.
The Motley Fool October 29, 2007 Brian Lawler	QLT in a Rut or Ready for a Comeback? QLT updates investors on its top drugs.
The Motley Fool July 17, 2007 Brian Lawler	QLT Stays the Course Sales of QLT's Visudyne, a drug to treat macular degeneration, continue to plummet due to competition. QLT plans to try to resuscitate.
The Motley Fool June 15, 2004 Charly Travers	QLT Swallows Atrix Atrix Laboratories has been purchased by Canadian drug company QLT. For Atrix shareholders, the timing of this deal must be incredibly frustrating.
The Motley Fool November 29, 2007 Brian Lawler	QLT Goes on the Block QLT announced yesterday that it's in the preliminary stages of exploring a sale.
The Motley Fool April 24, 2007 Brian Lawler	Is the Worst Over for QLT? The biopharma announces another dismal quarter of declining sales for its top compound.
The Motley Fool March 31, 2008 Brian Lawler	A Good Mix for QLT QLT takes one step closer toward a winning combination for those who suffer from macular degeneration.
The Motley Fool May 24, 2005 Charly Travers	Genentech Eyes a New Market Will Lucentis be the next addition to the biotech giant's growing drug portfolio? Investors, take note.
The Motley Fool January 3, 2005 Rich Duprey	Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA.
The Motley Fool August 31, 2007 Brian Lawler	QLT Gets Reformulated Drug developer QLT announced that an EU approval will open new markets for the cancer drug that could edge out the competition by lowering overall medical costs.
The Motley Fool March 29, 2005 Charly Travers	A Biotech Value Play Sometimes you have to invest against the grain. Take a look at Canadian drug company QLT.
The Motley Fool August 22, 2005 Rich Duprey	Fuzzy Outlook for OSI-Eyetech Merger OSI Pharmaceuticals appears to have little to gain from its purchase of Eyetech. The situation does offer an eye-opening lesson on the risks inherent in investing in such one-trick ponies.
The Motley Fool February 26, 2007 Brian Lawler	Is QLT the Comeback Kid? The Canadian drugmaker updates investors on its outlook for 2007.
The Motley Fool April 28, 2005 Charly Travers	QLT's a Clutch Performer Pharma continues to deliver growth through difficult times.
The Motley Fool January 18, 2005 Charly Travers	Biotech Class of 2004 Hot drugs are leading to amazing stock performances. CoTherix... Eyetech Pharmaceuticals... Pharmion... etc.
The Motley Fool January 5, 2005 Rich Duprey	Sharks Don't Go Blind Shark liver oil shows promise in treatment of age-related macular degeneration. Genaera Corp. though leading this interesting investigation, is not profitable, racking up some significant losses over the years.
BusinessWeek October 18, 2004 Gene G. Marcial	Is Pfizer Eyeing Eyetech? Pfizer may buy Eyetech after its Macugen ophthalmology product is approved. And a Merrill Lynch analyst calls Eyetech stock "a buy," saying it should turn profitable in 2005, earning 19 cents a share, and 81 cents in 2006.
The Motley Fool June 10, 2008 Brian Lawler	Allergan's Unblemished Deal Acquiring a niche acne drug from QLT provides clarity for both companies.
The Motley Fool June 8, 2007 Brian Lawler	QLT Eats Itself The beleaguered specialty pharmaceutical opens up another share buyback plan.
The Motley Fool March 18, 2008 Brian Lawler	QLT's Blemished Aczone Clears Up A more lenient label from the FDA is good news for this drugmaker.
The Motley Fool September 12, 2006 Brian Lawler	Those Buybacks at QLT Is the biopharmaceutical repurchasing shares to make itself more attractive for an acquisition? Investors, take note.
The Motley Fool May 31, 2005 Karl Thiel	Is Eyetech Better Than It Looks? If you're a born contrarian with a little spare mad money lying around, this biotech could be worth buying at these levels.
The Motley Fool April 19, 2004 Charly Travers	4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry.
BusinessWeek August 16, 2004 Arlene Weintraub	The Race to Stop an Eyesight Stealer No magic bullet yet, but new drugs to fight age-related macular degeneration are near.
The Motley Fool February 11, 2005 Stephen D. Simpson	For Alcon, the Eye Is the Prize Well-balanced growth continues to be the key to this ophthalmology giant.
The Motley Fool October 2, 2007 Brian Orelli	Regeneron Sees Positive Phase 2 Data Regeneron Pharmaceuticals and partner Bayer HealthCare see a bright future for their age-related macular degeneration treatment after announcing positive phase 2 data.
Managed Care March 2005 Thomas Morrow	Aptamers: Slowing Progression of AMD A single strand of nucleic acid may hold the key to treating the leading cause of severe vision loss and blindness resulting from age-related macular degeneration.
Chemistry World May 21, 2014 Phillip Broadwith	Novartis enhances its focus with eyecare deal Swiss pharma major Novartis is continuing its quest to excel in a few specialist fields by licensing rights to US firm Ophthotech's lead candidate, Fovista, for wet age-related macular degeneration.
The Motley Fool October 26, 2004 Charly Travers	Biotech's 5-Baggers: Part 2 Several hot drugs are generating smoking returns. If the goal for an investor is to aim for one of these five-baggers, then one option is to invest before the company passes through the inflection point.
The Motley Fool April 1, 2004 Charly Travers	Atrix Batting 1.000 Atrix Laboratories' drugs have breezed past the Food and Drug Administration.
The Motley Fool September 1, 2005 Stephen D. Simpson	Novartis Keeps Gorging Offering to buy the remainder of Chiron for $4.5 billion may up this company's execution risk over the next few quarters. Investors, take note.
The Motley Fool July 16, 2010 Brian Orelli	A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year.
The Motley Fool April 21, 2005 Stephen D. Simpson	Novartis' Triple Threat The Swiss drug giant boasts strong franchises in generics, cardiology, and oncology. It's hard not to think of Novartis as one of the highest-quality options in the pharmaceutical investing space.
The Motley Fool February 27, 2007 Billy Fisher	OSI Eyeing Growth in '07 Despite recent mixed results, the pharmaceutical has higher hopes for the year. Investors, take note.
Managed Care August 2006 Thomas Morrow	New Injectable Medication Effective Against Wet AMD Age-related macular degeneration is the most common cause of blindness in people over age 55. This market will expand rapidly. Managed care should remain informed and start to manage this area.
The Motley Fool January 22, 2007 Brian Lawler	Another Busy Year in Store for Novartis Trying to place a value on Novartis is a tough thing to do now with so many important drugs awaiting regulatory review and its addiction to acquisitions and divestitures making financial comparisons between the years tough.
The Motley Fool July 17, 2007 Brian Lawler	Still Strong at Novartis For investors who are willing to filter the negative news and are patient enough to wait for recently launched branded compounds to help its top-line growth, Novartis is worth a look
The Motley Fool June 7, 2006 Stephen D. Simpson	Novartis Can't Say No The Swiss drug giant signs more deals to boost its pipeline. Investors, here is a strong company in a weak sector that's still somewhat undervalued -- not exactly the worst story of the week.
The Motley Fool June 7, 2004 Brian Gorman	Novartis Nabs Sabex Novartis' purchase gives it a lifeline to the generics market.
The Motley Fool July 16, 2009 Brian Orelli	A Strong Dollar Can Hurt Novartis makes it through a hard quarter.
The Motley Fool December 21, 2004 Charly Travers	Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc.
The Motley Fool January 20, 2005 Stephen D. Simpson	Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error.